160 related articles for article (PubMed ID: 10187039)
21. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.
Kempton CL; Soucie JM; Abshire TC
J Thromb Haemost; 2006 Dec; 4(12):2576-81. PubMed ID: 17002659
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
[TBL] [Abstract][Full Text] [Related]
23. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
[TBL] [Abstract][Full Text] [Related]
24. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
[TBL] [Abstract][Full Text] [Related]
25. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
Addiego J; Kasper C; Abildgaard C; Hilgartner M; Lusher J; Glader B; Aledort L
Lancet; 1993 Aug; 342(8869):462-4. PubMed ID: 8102429
[TBL] [Abstract][Full Text] [Related]
26. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
28. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
Kreuz W; Ettingshausen CE; Zyschka A; Oldenburg J; Saguer IM; Ehrenforth S; Klingebiel T
Semin Thromb Hemost; 2002 Jun; 28(3):285-90. PubMed ID: 12098090
[TBL] [Abstract][Full Text] [Related]
29. Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer.
Suzuki T; Arai M; Miyasaka S; Watanabe J; Sugimura D; Amano K; Yamagishi T; Kagawa K; Fukue H; Fukutake K
Int J Hematol; 1995 Aug; 62(2):127-32. PubMed ID: 8590774
[TBL] [Abstract][Full Text] [Related]
30. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
[TBL] [Abstract][Full Text] [Related]
31. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
33. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
34. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.
Walker I; Poon MC
Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984
[No Abstract] [Full Text] [Related]
35. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
Chang H; Sher GD; Blanchette VS; Teitel JM
Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
[TBL] [Abstract][Full Text] [Related]
36. Induction of immune tolerance in patients with hemophilia A and inhibitors.
Gruppo RA; Valdez LP; Stout RD
Am J Pediatr Hematol Oncol; 1992; 14(1):82-7. PubMed ID: 1550269
[TBL] [Abstract][Full Text] [Related]
37. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
38. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
Josephson CD; Abshire T
Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
[TBL] [Abstract][Full Text] [Related]
39. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
[TBL] [Abstract][Full Text] [Related]
40. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
Duncan E; Collecutt M; Street A
Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
